Breadcrumbs Section. Click here to navigate to respective pages.
Pharmaceuticals, Health Economics and Market Access
The major advances in the field of biotechnology and molecular biology in the 21st century has led to a better understanding of pathophysiology of diseases. A new generation of biopharmaceuticals has emerged including a wide and heterogeneous range of innovative therapies. These aim to prevent or treat chronic or serious life-threatening diseases, previously considered incurable. This unique book series focuses on how the regulatory environment has evolved to analyse and review those therapies while HTA agencies and payers remain resistant. It provides insight into current learning, how those products will be accessible and which policy changes will be required to permit patient access.